# A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Study · id `cardio:ct-nct03619850` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03619850](<https://clinicaltrials.gov/study/NCT03619850>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03619850

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 129 participants.

## Technical summary

Registry record NCT03619850. Randomized; no masking; primary purpose treatment. Start 2018-08-13 (actual); primary completion 2026-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 129 participants (planned count; ClinicalTrials.gov record NCT03619850, source copy `cardio:ctgov-nct03619850-2026-04-17`, retrieved 2026-10-26)
- Started: 2018-08-13 (actual) (ClinicalTrials.gov record NCT03619850, source copy `cardio:ctgov-nct03619850-2026-04-17`, retrieved 2026-10-26)
- Primary completion: 2026-08-31 (anticipated) (ClinicalTrials.gov record NCT03619850, source copy `cardio:ctgov-nct03619850-2026-04-17`, retrieved 2026-10-26)
- Completion: 2026-08-31 (anticipated) (ClinicalTrials.gov record NCT03619850, source copy `cardio:ctgov-nct03619850-2026-04-17`, retrieved 2026-10-26)
- Countries: United States; Hungary; Lithuania; Mexico; Poland (ClinicalTrials.gov record NCT03619850, source copy `cardio:ctgov-nct03619850-2026-04-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03619850-2026-04-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- Condition: Chronic Kidney Disease; Iron Deficiency Anemia
- Intervention (Drug): Ferumoxytol
- Intervention (Drug): Iron sucrose
- Lead sponsor: AMAG Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AMAG Pharmaceuticals, Inc. (`cardio:org-amag-pharmaceuticals-inc`)

## Provenance

Content hash: e92f0ba4a7aa3b274d97969e7d61f1c9011d45be066421095ec85a6afbf61805
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
